ITGAM and prostate carcinoma: When we conducted quantitative FACS analysis on prostate cancer-associated immune cells, we found that B220+ B cells were almost completely depleted in BAY-D and BAY-I treated prostates, consistent with our previous study30, while CD11b+Gr-1+ MDSC did not change significantly (Supplementary Fig. 4B).